TIN

NOV 2 2 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1614

Applicant:

Steven C. Quay

Serial No.:

09/891,630

Filing Date:

June 25, 2001

Title:

Dopamine Agonist Formulations For Enhanced

**Central Nervous System Delivery** 

Attorney Docket No.:

2300-09-03

Examiner/Group Art:

Unknown/1614

## **CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited in the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 20th day of November, 2006.

Susan M. Wanger

Enclosure(s):

Response to Non-Compliant Amendment Copy of Non-Compliant Amendment Postcard

RE HOZ		
ans de	Application No.	Applicant(s)
Anjendment (37 CFR 1.121)	109/84/630	
	Examiner	A-ALI-G
		Art Unit
The MAU DIO DATE - EAL		
- The MAILING DATE of this communication app	pears on the cover sheet with the c	orrespondence address
The amendment document filed on	is considered non-compliant b	ecause it has failed to meet the
requirements of 37 CFR 1.121, in order for the amendm required.	nent document to be compliant, co	prection of the following item(s)
	•	. • •
THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE  1. Amendments to the specification:	AMENDMENT DOCUMENT TO I	BE NON-COMPLIANT:
A. Amended paragraph(s) do not include	markings	
B. New paragraph(s) should not be unde	rlined.	
C. Other		
2. Abstract:		
☐ A. Not presented on a separate sheet. 37☐ B. Other	CFR 1.72.	
<u> </u>		
3. Amendments to the drawings:		en e
A. The drawings are not properly identifie "Annotated Sheet" as required by 37 C		
L. B. The practice of submitting proposed drawing correction has been eliminated by		
showing amended figures, without man	kings, in compliance with 37 CFR	1.84 are required.
4. Amendments to the claims:  A. A complete listing of all of the claims is		
L. B. The listing of claims does not include the	a text of all ponding dalms (s-s).	#3
(Previously presented), (New), (Not en	tatus identifiers: (Onginal), (Currel fered), (Withdrawa), and (Mithdrawa)	ntly amended), (Canceled),
22. The Gailto of this affertoment paper n	ave not been presented in ascend	vn-currently amended). ing numerical order
15 15 15	2 (M(22(M)))	
For further explanation of the amendment format required http://www.uspto.gov/web/offices/pac/dapp/opla/preogned	by 37 CFR 1.121, see MPEP § 7	14 and the USPTO website at
http://www.uspto.gov/web/offices/pac/dapp/opla/preognor	ice/officeflyer.pdf.	The state of the s
TIME PERIODS FOR FILING A REPLY TO THIS NOTICE	F:	
Applicant is given no new time period if the non-confiled after allowance. If applicant wishes to resubmit to		
arrange de l'estratifie de l'estratification de l'e	num the time period set forth in th	e final Office action
2. Applicant is given one month, or thirty (30) days, whi	chaverie langer from the mail da	(
	in minnigheo umh 37 eeta 4 494	16 Alan
amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension		
period under 37 CFR 1.103(a) or (c), and an amendm	ent filed in response to a Quarte	ment filed within a suspension
( ) ( ) ( ) ( ) ( )	was mod in response to a Quayle ;	action.
Extensions of time are available under 37 CFR 1.	136(a) only if the non-compliant a	mendment is a new seed
amendment or an amendment filed in response to	a Quayle action.	ineridinent is a non-inal
Failure to timely respond to this notice will result  Abandonment of the application if the non-com	III; pliant amendment is a sec sector	
Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action; or		
Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental		
amendment.		
(x)110m00		72-0560
Legal Instruments Examiner (LIE)	Tel	72-0560 ephone No.

U.S. Patent and Trademark Office PTOL-324 (08-05)